RCKT Rocket Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q May 7, 2026RCKT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
RCKT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Jan. 5, 2018 | 1-for-4 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | RCKT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 1.2 | · | 2.4 | Undervalued | |
| Price / Tangible Book (MRQ) | 1.3 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | RCKT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 6.1 | · | 6.1 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-0.48 | $0.25 | -294.6% |
| March 31, 2026 | $-0.42 | $-0.42 | -1.2% | |
| Dec. 31, 2025 | $-0.38 | $-0.46 | 17.8% | |
| Sept. 30, 2025 | $-0.45 | $-0.52 | 12.6% | |
| June 30, 2025 | $-0.59 | $-0.57 | -3.9% | |
| March 31, 2025 | $-0.56 | $-0.63 | 10.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q1 2026 |
|---|---|---|
| Revenue | $0 | |
| R&D Expense | $31M | |
| SG&A Expense | $17M | |
| Operating Expenses | $49M | |
| Operating Income | $-49M | |
| Interest Expense | $473.0K | |
| Net Income | $-48M | |
| EPS (Basic) | $-0.42 | |
| EPS (Diluted) | $-0.42 | |
| Shares (Basic) | 112,134,059 | |
| Shares (Diluted) | 112,134,059 | |
| EBITDA | $-47M |
Balance Sheet
| Metric | Trend | Q1 2026 |
|---|---|---|
| Cash & Equivalents | $50M | |
| Short-term Investments | $95M | |
| Prepaid Expense | $5M | |
| Current Assets | $150M | |
| PP&E (Net) | $27M | |
| PP&E (Gross) | $57M | |
| Accum. Depreciation | $31M | |
| Goodwill | $39M | |
| Intangibles | $25M | |
| Total Assets | $285M | |
| Accounts Payable | $22M | |
| Current Liabilities | $24M | |
| Capital Leases | $2M | |
| Other Non-current Liabilities | $1M | |
| Total Liabilities | $47M | |
| Common Stock | $1M | |
| Paid-in Capital | $1.73B | |
| Retained Earnings | $-1.49B | |
| AOCI | $-112.0K | |
| Stockholders' Equity | $238M | |
| Liabilities + Equity | $285M | |
| Shares Outstanding | 109,123,671 |
Cash Flow
| Metric | Trend | Q1 2026 |
|---|---|---|
| D&A | $2M | |
| Stock-based Comp | $8M | |
| Restructuring | $-46.0K | |
| Other Non-cash | $-8M | |
| Operating Cash Flow | $-45M | |
| CapEx | $93.0K | |
| Investing Cash Flow | $17M | |
| Financing Cash Flow | $-1.0K | |
| Free Cash Flow | $-45M |
Profitability
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -12.6% | |
| ROE | -14.6% |
Liquidity & Solvency
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 6.1 | |
| Quick Ratio | 5.9 | |
| Interest Coverage | -102.6 |
Efficiency
| Metric | Trend | Q1 2026 |
|---|---|---|
| Asset Turnover | 0.0 |
Per Share
| Metric | Trend | Q1 2026 |
|---|---|---|
| Book Value / Share | $2.18 | |
| Revenue / Share | $0.00 | |
| Cash Flow / Share | $-0.40 | |
| Cash / Share | $0.45 |
Valuation (TTM)
| Metric | Trend | Q1 2026 |
|---|---|---|
| Market Cap | $391M | |
| P/B | 1.6 | |
| P / Tangible Book | 2.2 | |
| P / Cash Flow | -8.6 |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 193 filers · $378.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 19 (-34 vs prior Q) | 33 (+4 vs prior Q) | 71 (-10 vs prior Q) | 65 (+16 vs prior Q) | +2.9M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | $60,492,180 | 17,687,772 | 15.98% | Shares |
| BlackRock, Inc. | $33,939,951 | 9,923,962 | 8.97% | Shares |
| VANGUARD GROUP INC | $29,990,925 | 8,544,423 | 7.92% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $19,870,313 | 5,810,033 | 5.25% | Shares |
| CITIGROUP INC | $16,640,184 | 4,865,551 | 4.40% | Shares |
| MARSHALL WACE, LLP | $13,780,075 | 4,029,262 | 3.64% | Shares |
| MILLENNIUM MANAGEMENT LLC | $13,681,176 | 4,000,344 | 3.61% | Shares |
| Newtyn Management, LLC | $13,680,000 | 4,000,000 | 3.61% | Shares |
| MAVERICK CAPITAL LTD | $13,419,953 | 3,923,963 | 3.55% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $12,942,604 | 3,784,387 | 3.42% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $11,580,675 | 3,386,162 | 3.06% | Shares |
| GOLDMAN SACHS GROUP INC | $9,690,320 | 2,833,427 | 2.56% | Shares |
| Monaco Asset Management SAM | $8,483,201 | 2,480,468 | 2.24% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $8,109,758 | 2,370,729 | 2.14% | Shares |
| FEDERATED HERMES, INC. | $7,880,388 | 2,304,207 | 2.08% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $6,754,144 | 1,974,896 | 1.78% | Shares |
| JPMORGAN CHASE & CO | $6,700,952 | 1,988,413 | 1.77% | Shares |
| TWO SIGMA ADVISERS, LP | $6,544,925 | 1,864,651 | 1.73% | Shares |
| STATE STREET CORP | $6,224,814 | 1,820,121 | 1.64% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $3,848,757 | 1,125,500 | 1.02% | Shares |
| MORGAN STANLEY | $3,633,827 | 1,062,522 | 0.96% | Shares |
| Opaleye Management Inc. | $3,420,000 | 1,000,000 | 0.90% | Shares |
| D. E. Shaw & Co., Inc. | $3,250,888 | 950,552 | 0.86% | Shares |
| Jump Financial, LLC | $2,968,218 | 867,900 | 0.78% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $2,711,971 | 792,974 | 0.72% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,561,830 | 749,073 | 0.68% | Shares |
| NORTHERN TRUST CORP | $2,514,008 | 735,090 | 0.66% | Shares |
| BANK OF AMERICA CORP /DE/ | $2,512,277 | 734,584 | 0.66% | Shares |
| Prosight Management, LP | $2,394,000 | 700,000 | 0.63% | Shares |
| Point72 Asset Management, L.P. | $2,293,202 | 670,527 | 0.61% | Shares |
| Qube Research & Technologies Ltd | $2,205,452 | 644,869 | 0.58% | Shares |
| Woodline Partners LP | $2,192,979 | 641,222 | 0.58% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,027,526 | 592,844 | 0.54% | Shares |
| FMR LLC | $1,669,981 | 488,299 | 0.44% | Shares |
| IEQ CAPITAL, LLC | $1,505,672 | 440,255 | 0.40% | Shares |
| ADAR1 Capital Management, LLC | $1,489,410 | 435,500 | 0.39% | Shares |
| Aberdeen Group plc | $1,360,226 | 397,727 | 0.36% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,323,762 | 387,065 | 0.35% | Shares |
| Invesco Ltd. | $1,310,941 | 383,316 | 0.35% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $1,190,479 | 348,093 | 0.31% | Shares |
| Susquehanna Portfolio Strategies, LLC | $1,135,803 | 332,106 | 0.30% | Shares |
| LPL Financial LLC | $1,100,679 | 321,836 | 0.29% | Shares |
| TWO SIGMA INVESTMENTS, LP | $1,079,903 | 315,761 | 0.29% | Shares |
| BIT Capital GmbH | $1,019,160 | 298,000 | 0.27% | Shares |
| AMERIPRISE FINANCIAL INC | $940,531 | 275,009 | 0.25% | Shares |
| Bank of New York Mellon Corp | $888,548 | 259,809 | 0.23% | Shares |
| Privium Fund Management B.V. | $834,979 | 244,146 | 0.22% | Shares |
| M28 Capital Management LP | $721,179 | 210,871 | 0.19% | Shares |
| ALLIANCEBERNSTEIN L.P. | $700,427 | 195,650 | 0.19% | Shares |
| UBS Group AG | $689,616 | 201,642 | 0.18% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RTW Investments, LP, Roderick Wong, M.D. ×8 filings | Sept. 19, 2023 | · | Initial filing | · | SEC |
| Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C., Robert Atchinson, Phillip Gross ×3 filings | Jan. 19, 2018 | · | Initial filing | · | SEC |
| Care Capital III LLC, Care Capital Investments III LP, Care Capital Offshore Investments III LP, Care Capital II LLC, Care Capital Investments II LP, Care Capital Offshore Investments II LP ×2 filings | Aug. 3, 2017 | · | Initial filing | · | SEC |
| Devon Park Bioventures, L.P. ×2 filings | Jan. 6, 2017 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 39 insiders · 14 officers · 22 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gaurav Shah | CEO | May 21, 2026 M | 1,061,724 | 0 | 6 | $-268,515 |
| Aaron Ondrey | Chief Financial Officer | July 3, 2025 S | 128,173 | 0 | 0 | $0 |
| Carlos Garcia-Parada | Chief Financial Officer | Feb. 14, 2022 A | · | 0 | 0 | $0 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | May 20, 2025 S | 441,927 | 0 | 0 | $0 |
| Christopher James Stevens | Chief Operating Officer | Feb. 11, 2026 A | 469,129 | 0 | 0 | $0 |
| Martin Wilson | General Counsel | Sept. 11, 2026 S | 598,489 | 0 | 6 | $-320,422 |
| John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | May 26, 2026 A | 89,780 | 0 | 9 | $-138,232 |
| Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | May 7, 2026 S | 267,510 | 0 | 1 | $-67,776 |
| Syed Ali-Aamir Rizvi | Chief Medical Officer | Feb. 11, 2026 A | 407,874 | 0 | 0 | $0 |
| Jonathan David Schwartz | Chief Science & Gene Therapy Officer | Nov. 18, 2025 S | 299,064 | 0 | 1 | $-7,584 |
| Mark Andrew White | General Manager, Commercial Affairs | Oct. 31, 2024 S | 69,140 | 0 | 0 | $0 |
| Kamran Alam | SVP - Finance & PFO | Feb. 10, 2020 A | · | 0 | 0 | $0 |
| Rudolph Baumgartner | Executive Vice President, Chief Medical Officer | Jan. 23, 2017 A | · | 0 | 0 | $0 |
| William K. Mcvicar | Executive Vice President, Chief Scientific Officer | March 22, 2016 A | · | 0 | 0 | $0 |
| Peter Fong | Director | June 18, 2026 A | 76,195 | 0 | 0 | $0 |
| Fady Ibraham Malik | Director | June 18, 2026 A | 52,862 | 0 | 0 | $0 |
| Roderick Wong, M.D. | Director | June 18, 2026 A | 75,499 | 0 | 0 | $0 |
| Mikael Dolsten | Director | June 18, 2026 A | 67,082 | 0 | 0 | $0 |
| Carsten Boess | Director | June 18, 2026 A | 52,862 | 0 | 0 | $0 |
| David P Southwell | Director | June 18, 2026 A | 54,522 | 0 | 0 | $0 |
| Elisabeth Bjork | Director | Jan. 2, 2026 P | 50,000 | 1 | 0 | $34,400 |
| Piratip Pratumsuwan | Director | June 18, 2025 A | 30,000 | 0 | 0 | $0 |
| Gotham Makker | Director | June 18, 2025 A | 415,346 | 0 | 0 | $0 |
| Pedro P Granadillo | Director | June 18, 2025 A | 54,734 | 0 | 0 | $0 |
| Keith Woods | Director | June 13, 2024 A | · | 0 | 0 | $0 |
| Naveen Yalamanchi | Director | June 13, 2024 A | 113,641 | 0 | 0 | $0 |
| Richard N. Spivey | Director | June 20, 2017 A | · | 0 | 0 | $0 |
| Patrick Machado | Director | June 20, 2017 A | · | 0 | 0 | $0 |
| Martin J Carroll | Director | June 20, 2017 A | 10,000 | 0 | 0 | $0 |
| Paul G Howes | Director | June 20, 2017 A | · | 0 | 0 | $0 |
| Gary M. Phillips | Director | June 20, 2017 A | · | 0 | 0 | $0 |
| BARBERICH TIMOTHY J | Director | June 20, 2017 A | · | 0 | 0 | $0 |
| Ittai Harel | Director | June 24, 2015 A | · | 0 | 0 | $0 |
| Isai Peimer | Director | June 24, 2015 A | · | 0 | 0 | $0 |
| Martin Vogelbaum | Director | June 24, 2015 A | · | 0 | 0 | $0 |
| Argeris N Karabelas | Director | June 24, 2015 A | 2,277,139 | 0 | 0 | $0 |
| Devang Kantesaria | 10% owner | Feb. 23, 2015 C | 3,243,709 | 0 | 0 | $0 |
| MedImmune Ventures, Inc. | 10% owner | Feb. 23, 2015 C | 1,917,906 | 0 | 0 | $0 |
| Dale Ritter | · | Jan. 17, 2017 M | 19,827 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 24 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.76% | 113,024 NS | July 31, 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0.11% | 127,633.38 | Oct. 1, 2026 | Daily |
| IWC · iShares Trust | 0.07% | 306,125 SH | Sept. 11, 2026 | Daily |
| GTO · Invesco Actively Managed Exchange-T… | 0.07% | 2,021,978.74 | Oct. 1, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 292,827 SH | Oct. 1, 2026 | Daily |
| IBB · iShares Trust | 0.03% | 806,601 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 78,767 SH | Aug. 19, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.02% | 7,755 SH | Oct. 1, 2026 | Daily |
| IWM · iShares Trust | 0.01% | 2,328,775 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 519,829 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 43,197 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 253,178 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 6,600 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 9,894 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 81,226 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 119,847 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.00% | 14,185 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 29,861 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 19,202 SH | Sept. 10, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1,000,868 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2,700,288 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 5,568 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.00% | 259,981 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 839,774 SH | Sept. 11, 2026 | Daily |
RCKT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
12 analysts · 2026-09-20Mean target $8.85 +245.9%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RCKT | · | · | · | · | · | · |
| PRLD | · | -2.2 | 73.4% | -819.6% | -137.7% | · |
| LXEO | $725M | -5.3 | · | · | -51.9% | · |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | · |
| UPB | $1.47B | -10.2 | 20.4% | -5026.0% | -38.3% | · |
| VNDA | $521M | -2.4 | 8.7% | -102.0% | -54.2% | · |
| FATE | $113M | -0.9 | -51.2% | -2051.1% | -58.2% | · |
| IKT | $270M | -4.2 | 111.0% | -1299.0% | -38.2% | · |
| ZSQR | · | · | · | · | · | · |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | · |
| SABS | · | · | · | · | · | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.